Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q2 2026

Q2 2026 biggest moves
  • COGTCOGT

    Cogent Biosciences

    Cut 45%

    now 2.0% of portfolio

  • GMABGMAB

    Genmab

    2.8× the shares

    now 2.0% of portfolio

  • MLYSMLYS

    Mineralys Therapeutics

    New

    1.1% of portfolio

  • CPRXCPRX

    CATALYST PHARMACEUTICALS

    Sold out

    was 1.2% of portfolio

52 changes in all

Top Holdings82 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

17.2M$2.1B22.2%——
20 qtrssince 2021-Q3
Unchanged
0
306.9M$585.7M6.1%——
3 qtrssince 2025-Q4
Unchanged
0
RVMD

Revolution Medicines, Inc.

2.4M$448M4.7%$35.80+423.11%
26 qtrssince 2020-Q1
Increased
60
PRAX

Praxis Precision Medicines, Inc.

963,351$322.5M3.4%$74.95+346.68%
6 qtrssince 2025-Q1
Unchanged
0
VTRS

Viatris Inc.

20.2M$320.9M3.3%$11.15+41.35%
23 qtrssince 2020-Q4
Unchanged
0
CNC

Centene Corporation

4.9M$314.6M3.3%$46.26+38.76%
27 qtrssince 2019-Q4
Decreased
0
200M$251.7M2.6%——
1 qtr
New
80
UTHR

United Therapeutics Corporation

457,000$247.6M2.6%$318.01+70.38%
6 qtrssince 2025-Q1
Unchanged
0
200M$240.5M2.5%——
2 qtrssince 2026-Q1
Unchanged
0
LEGN
LEGN
ADR

Legend Biotech Corporation

8.1M$235M2.5%$25.75+12.14%
7 qtrssince 2024-Q4
Increased
56
COGT

Cogent Biosciences, Inc.

5M$193.7M2.0%$12.67+205.47%
23 qtrssince 2020-Q4
Decreased
0
GMAB
GMAB
ADR

Genmab A/S

6.9M$188.6M2.0%$27.24+0.84%
2 qtrssince 2026-Q1
Increased
78
BKD

Brookdale Senior Living Inc.

11.6M$187.2M2.0%$4.41+264.81%
27 qtrssince 2019-Q4
Unchanged
0
VERA

Vera Therapeutics, Inc.

3.9M$168.1M1.8%$27.66+55.11%
6 qtrssince 2025-Q1
Increased
50
IONS

Ionis Pharmaceuticals, Inc.

2M$157M1.6%$65.42+21.20%
4 qtrssince 2025-Q3
Unchanged
0
CELC

Celcuity Inc.

1.5M$151.8M1.6%$78.20+33.79%
4 qtrssince 2025-Q3
Decreased
0
BCRX

BioCryst Pharmaceuticals, Inc.

15.1M$151M1.6%$7.43+34.61%
14 qtrssince 2023-Q1
Increased
48
NAMS

NewAmsterdam Pharma Company N.V.

4.3M$144.5M1.5%$23.84+42.15%
10 qtrssince 2024-Q1
Unchanged
0
ACHC

Acadia Healthcare Company, Inc.

4.5M$133.5M1.4%$16.97+74.01%
4 qtrssince 2025-Q3
Unchanged
0
TNGX

Tango Therapeutics, Inc.

4.2M$131M1.4%$12.66+146.88%
3 qtrssince 2025-Q4
Increased
48
$9.6B
AUM
82
Positions
Q2 2026
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q1$5,064,779,427-4.07625969013%
2025-Q2$5,509,809,2648.78675652937%
2025-Q3$6,550,740,15118.8923216236%
2025-Q4$7,830,165,97019.5310116034%
2026-Q1$8,476,379,7168.25287418525%
2026-Q2$9,586,027,94413.0910632272%
Activity profile
$ moved · Q2'26
New27%Increased27%Decreased22%Exited24%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.9 years
<1Q12%1-4Q10%1-2Y2%2Y+76%

Deerfield Management Company, L.P. manages $9.6B across 82 positions as of Q2 2026. Top holdings: NUVL (22.2%), BROOKDALE SR LIVING INC (6.1%), RVMD (4.7%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$10B
NUVL22.22%
BROOKDALE SR6.11%
RVMD4.67%
PRAX3.36%
VTRS3.35%
CNC3.28%
REVOLUTION M2.63%
UTHR2.58%
ARROWHEAD PH2.51%
LEGN2.45%
Other2.02%

Portfolio allocation by GICS sector

Sectors1
Healthcare100.00%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used